Zimmer Partners’s Kalaris Therapeutics KLRS Stock Holding History

Zimmer Partners’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,087	Closed	-$688K	–	174
2020 Q3	$688K	Buy	+1,087	New	+$742K	0.01%	104

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Zimmer Partners's KLRS Position: Q4 2020 in Review

Zimmer Partners sold out of Kalaris Therapeutics (KLRS) in Q4 2020, closing a stake of 1,087 shares — an estimated $688K sold.

Zimmer Partners first reported a position in KLRS in Q3 2020 and held it in 1 quarter. The position peaked at $688K in Q3 2020. 71 funds tracked by Wall St. Rank hold KLRS as of Q4 2020.

Zimmer Partners reported no remaining Kalaris Therapeutics position as of Q4 2020 after selling out during the quarter.
Zimmer Partners sold 1,087 Kalaris Therapeutics shares in Q4 2020, an estimated $688K.
Zimmer Partners first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 1 quarter.
Zimmer Partners's Kalaris Therapeutics position peaked at $688K in Q3 2020.
71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2020.

Based on Zimmer Partners's 13F filing for Q4 2020, filed 16 Feb 2021.